On behalf of Warner Law Offices PLLC | Feb 19, 2018 | Dangerous Or Defective Products, Defective Drugs
Warner Law Offices has recently become aware that the Type 2 diabetes drug, Invokana, puts users at an increased risk for leg, foot and toe amputations. The FDA issued the first safety warning regarding Invokana and amputation based on interim analysis of two...
On behalf of Warner Law Offices PLLC | Mar 27, 2017 | Defective Drugs
According to an observational study published in JAMA Internal Medicine, people taking Xarelto (rivaroxaban) may be more likely to have a serious bleeding event than those taking Pradaxa (dabigatran). Johnson and Johnson (J&J) is facing more the 15,000 Xarelto...
On behalf of Warner Law Offices PLLC | Nov 3, 2016 | Defective Drugs
By: Attorney Bobby WarnerThe February 2016 issue of JAMA, the Journal of the American Medical Association, published results of a study which indicated that long-term use of Proton Pump Inhibitor (PPI) medications such as Prilosec, Nexium and Prevacid may increase the...
On behalf of Warner Law Offices PLLC | Aug 19, 2016 | Defective Drugs
A study recently published by JAMA Pediatrics has provided evidence that acetaminophen, the active ingredient in Tylenol and other over the counter medications, could cause a pregnant mother’s offspring to have a hyperactivity disorder.Details of the StudyThe...
On behalf of Warner Law Offices PLLC | Aug 18, 2016 | Defective Drugs
Invokana and Invokamet (canagliflozin), Farxiga, and Xigduo XR (dapagliflozin) are drugs used to lower blood sugar in Type 2 diabetes. They are very popular drug, but unfortunately they have been associated with acute kidney damage. There was already a warning about...
On behalf of Warner Law Offices PLLC | Jun 4, 2013 | Defective Drugs
Some popular drugs used to treat Type 2 diabetes have come under scrutiny after a new research indicates that some diabetes drugs may cause pancreatic changes that can lead to pancreatic cancer. The drugs studied were Januvia, Byetta and some other diabetes drugs...
